marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-08-2024
Ligand Pharmaceuticals Incorporated Balance Sheet 2011-2024 | LGND
Annual Balance Sheet Ligand Pharmaceuticals Incorporated
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-22.5 M | -44.3 M | -18.1 M | 396 M | 1.57 B | 519 M | 223 M | 224 M | 211 M | 36 M | -2.53 M | 15.9 M | 19.4 M |
Long Term Debt |
19 K | 5 K | 58 K | 442 M | 639 M | 610 M | 18.9 M | 29.6 M | 205 M | 196 M | - | 13.4 M | 20.3 M |
Long Term Debt Current |
403 K | 670 K | 1.37 M | 1.88 M | 1.24 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 711 M | 618 M | 32.4 M | 33.2 M | 209 M | 211 M | 26.2 M | 42.3 M | 70.1 M |
Total Current Liabilities |
16.8 M | 98.8 M | 41.7 M | 100 M | 17 M | 82.2 M | 239 M | 227 M | 223 M | 22.8 M | 28.9 M | 35.4 M | 43.6 M |
Total Liabilities |
86.3 M | 165 M | 476 M | 653 M | 728 M | 700 M | 271 M | 260 M | 230 M | 234 M | 55.1 M | 77.8 M | 114 M |
Deferred Revenue |
1.22 M | 355 K | 654 K | 29.4 M | 2.14 M | 3.29 M | 173 K | - | - | 150 K | 116 K | 486 K | 1.24 M |
Retained Earnings |
503 M | 451 M | 449 M | 392 M | 400 M | -229 M | -401 M | -431 M | -402 M | -659 M | -671 M | -683 M | -682 M |
Total Assets |
787 M | 763 M | 1.3 B | 1.36 B | 1.49 B | 1.26 B | 671 M | 602 M | 534 M | 258 M | 105 M | 104 M | 122 M |
Cash and Cash Equivalents |
23 M | 45 M | 19.5 M | 48 M | 71.5 M | 117 M | 20.6 M | 18.8 M | 97.4 M | 160 M | 11.6 M | 12.4 M | 7.04 M |
Book Value |
701 M | 597 M | 821 M | 710 M | 767 M | 561 M | 400 M | 341 M | 304 M | 24.4 M | 49.6 M | 26.5 M | 8.65 M |
Total Shareholders Equity |
701 M | 597 M | 821 M | 710 M | 767 M | 561 M | 400 M | 341 M | 237 M | 26.3 M | 49.6 M | 26.5 M | 8.18 M |
All numbers in USD currency
Quarterly Balance Sheet Ligand Pharmaceuticals Incorporated
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.27 M | 6.42 M | 5.19 M | 5.76 M | 5.83 M | 11 M | 11.2 M | 10.3 M | 14 K | 27 K | 39 K | 58 K | 72 K | 315 M | 352 M | 112 K | 112 K | 442 M | 442 M | 71 K | 639 M | 639 M | 639 M | 610 M | 610 M | 610 M | 610 M | - | - | - | - | - | - | - | 205 M | - | 203 M | - | 202 M | 196 M | 194 M | 196 M | 196 M | - | - | - | - | 27.5 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
114 M | 91.2 M | 107 M | 86.3 M | 101 M | 93.2 M | 165 M | 165 M | 234 M | 274 M | 312 M | 476 M | 462 M | 470 M | 549 M | 653 M | 653 M | 653 M | 653 M | 728 M | 728 M | 728 M | 728 M | 700 M | 700 M | 700 M | 700 M | 252 M | 252 M | 252 M | 252 M | 231 M | 231 M | 231 M | 231 M | 226 M | 226 M | 226 M | 226 M | 234 M | 234 M | 234 M | 234 M | 55.1 M | 55.1 M | 55.1 M | 55.1 M | 77.8 M | 77.8 M | 77.8 M | 77.8 M | 104 M | 104 M | 104 M | 104 M |
Deferred Revenue |
1.15 M | 1.2 M | 1.23 M | 1.22 M | - | - | 257 K | 355 K | 9.55 M | 10.6 M | 10.5 M | 11 M | 12 M | 17.1 M | 25.1 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 2.14 M | 2.14 M | 2.14 M | 2.14 M | 3.29 M | 3.29 M | 3.29 M | 75 K | 173 K | 1.08 M | - | - | - | - | - | - | - | 34 K | 300 K | 67 K | 1.06 M | 114 K | 1.06 M | 150 K | 116 K | 116 K | 116 K | 116 K | 486 K | 486 K | 486 K | 486 K | 1.24 M | 1.24 M | 1.24 M | 1.24 M |
Retained Earnings |
530 M | 537 M | 589 M | 503 M | 485 M | 495 M | 493 M | 451 M | 468 M | 468 M | 469 M | 449 M | 455 M | 441 M | 410 M | 392 M | 392 M | 392 M | 392 M | 400 M | 400 M | 400 M | 400 M | -229 M | -229 M | -229 M | -229 M | -401 M | -401 M | -401 M | -401 M | -431 M | -431 M | -431 M | -431 M | -429 M | -429 M | -429 M | -429 M | -659 M | -659 M | -659 M | -659 M | -671 M | -671 M | -671 M | -671 M | -683 M | -683 M | -683 M | -683 M | -682 M | -682 M | -682 M | -682 M |
Total Assets |
955 M | 866 M | 914 M | 787 M | 769 M | 758 M | 811 M | 763 M | 1.05 B | 1.08 B | 1.11 B | 1.3 B | 1.27 B | 1.26 B | 1.3 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B | 1.49 B | 1.49 B | 1.49 B | 1.49 B | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 671 M | 671 M | 671 M | 671 M | 602 M | 602 M | 602 M | 602 M | 503 M | 503 M | 503 M | 503 M | 258 M | 258 M | 258 M | 258 M | 105 M | 105 M | 105 M | 105 M | 104 M | 104 M | 104 M | 104 M | 121 M | 121 M | 121 M | 121 M |
Cash and Cash Equivalents |
63.6 M | 18.1 M | 50.1 M | 23 M | 19.9 M | 28.4 M | 88.7 M | 45 M | 4.12 M | 5.28 M | 15 M | 19.5 M | 23.4 M | 22 M | 31.9 M | 48 M | 47.6 M | 47.6 M | 47.6 M | 71.5 M | 71.5 M | 71.5 M | 71.5 M | 117 M | 117 M | 117 M | 117 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 97.4 M | 97.4 M | 97.4 M | 97.4 M | 160 M | 160 M | 160 M | 160 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 7.04 M | 7.04 M | 7.04 M | 7.04 M |
Book Value |
841 M | 775 M | 807 M | 701 M | 668 M | 665 M | 646 M | 597 M | 816 M | 802 M | 793 M | 821 M | 812 M | 787 M | 746 M | 710 M | 710 M | 710 M | 710 M | 767 M | 767 M | 767 M | 767 M | 561 M | 561 M | 561 M | 561 M | 419 M | 419 M | 419 M | 419 M | 371 M | 371 M | 371 M | 371 M | 277 M | 277 M | 277 M | 277 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 49.6 M | 49.6 M | 49.6 M | 49.6 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M |
Total Shareholders Equity |
841 M | 775 M | 807 M | 701 M | 668 M | 665 M | 646 M | 597 M | 816 M | 802 M | 793 M | 821 M | 812 M | 787 M | 746 M | 710 M | 710 M | 710 M | 710 M | 767 M | 767 M | 767 M | 767 M | 561 M | 561 M | 561 M | 561 M | 400 M | 400 M | 400 M | 400 M | 341 M | 341 M | 341 M | 341 M | 237 M | 237 M | 237 M | 237 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 49.6 M | 49.6 M | 49.6 M | 49.6 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 8.18 M | 8.18 M | 8.18 M | - |
All numbers in USD currency